Is OGN Worth Buying in 2026?

Organon & Co.

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-04-19

Here’s whether Organon & Co. (OGN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.

🔵
Neutral

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 3-month momentum positive (+11.4%); rising volume confirms the move (1.81x 30d avg). Concerns: 50-day MA is falling (-2.43% over 10 days); RSI 83 — overbought, elevated pullback risk. Currently 26.3% off its 52-week high. Score: +3/7.

Ready to act on this? 📈 Trade on Webull

OGN is in a confirmed uptrend, trading above both its 50-day ($7.08) and 200-day ($8.37) moving averages. With an RSI of 83.1, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -9.8% compares to +35.1% for SPY (trailed the market by 44.9%). The current 26.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $9,020 today
vs. S&P 500 (SPY) — same period trailed market by 44.9%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($8.37)
Above 50-day MA ($7.08)
!RSI(14) neutral zone (30–70) — currently 83.1
Positive return (-9.8%)
!Within 10% of period high (−26.3%)
Period Range $9.76
$5.69 $13.25
RSI (14) 83.1
0 · OversoldOverbought · 100

Key Metrics

Price$9.76
Period Return-9.8%
Period High$13.25
Period Low$5.69
Drawdown−26.3%
MA-50$7.08
MA-200$8.37
RSI (14)83.1
Avg Volume (30d)6.0M
vs. SPYtrailed by 44.9%
Return Rank#758 of 996

Trade OGN

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers